HL
HLS Therapeutics Inc.
HLTRF · OTC
$2.82 +0.00% (+$0.00)
1M +3.30%
Market Cap $88.2M
P/E Ratio -
Div. Yield -
ROE 14.43%
Bulios Fair Price
$3.97
40.8% upside
Current Price
$2.82
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HLTRF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
98 /100
Cheap EV/EBITDA 6.34x
P/S 1.57x
P/FCF 4.98x
Growth
39 /100
Stable Rev. growth 2.79%
FCF growth 32.51%
Book val. growth 21.10%
Profitability
50 /100
Moderate Gross margin 61.41%
Net margin 15.20%
FCF margin 31.49%
Quality
5 /100
Poor ROIC 3.99%
ROE 14.43%
Asset turnover 0.44x
Debt
52 /100
Moderate Debt/Equity 0.76x
Current ratio 1.05x
Net debt/EBITDA 1.54x
Stability
77 /100
Stable Beta 0.84x
Rev. volatility 6.74%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HLTRF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Craig Stuart Millian
Employees
85
Headquarters
Etobicoke
Upcoming events
12 NOV
Earnings
Upcoming earnings report